FAQ

ON 01910

Known as: ON-01910, ON01910 
 

Topic mentions per year

Topic mentions per year

2005-2018
01220052018

Related topics

Related topics

4 relations

Broader (2)

GlycineSulfones

Narrower (2)

ON 01910.Narigosertib

Related mentions per year

Related mentions per year

1936-2018
19401960198020002020
ON 01910
Glycine
Sulfones
rigosertib
ON 01910.Na

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Combined effects of PLK1 and RAS in hepatocellular carcinoma reveal rigosertib as promising novel therapeutic “dual-hit” option
Inhibition of RAS-RAF-ERK-signaling is a major mechanism mediated by the multi-kinase inhibitors sorafenib and regorafenib, the… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2016
2016
Erythroblast enucleation is a dynein-dependent process.
Mammalian erythroblasts undergo enucleation through a process thought to be similar to cytokinesis. Microtubule-organizing… (More)
Is this relevant?
2014
2014
Discovery of (E)-3-((styrylsulfonyl)methyl)pyridine and (E)-2-((styrylsulfonyl)methyl)pyridine derivatives as anticancer agents: synthesis, structure-activity relationships, and biological activities…
ON01910.Na is a highly effective anticancer agent that induces mitotic arrest and apoptosis. Clinical studies with ON01910 in… (More)
  • table 1
  • figure 1
  • table 2
  • table 3
  • figure 2
Is this relevant?
2013
2013
A Novel Anti-Tumor Inhibitor Identified by Virtual Screen with PLK1 Structure and Zebrafish Assay
Polo-like kinase 1 (PLK1), one of the key regulators of mitosis, is a target for cancer therapy due to its abnormally high… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2012
2012
Preclinical Pharmacokinetic and Pharmacodynamic Evaluation of Novel Anticancer Agents, ON01910.Na (Rigosertib, Estybon™) and ON013105, for Brain Tumor Chemotherapy
To evaluate a mitotic inhibitor, ON01910.Na, as a potential chemotherapeutic agent for brain tumors using a series of PK/PD… (More)
  • figure 1
  • figure 2
  • table I
  • table II
  • table III
Is this relevant?
2012
2012
Dissecting the phenotypes of Plk1 inhibition in cancer cells using novel kinase inhibitory chemical CBB2001
Polo-like kinase 1 (Plk1) is a mitotic serine/threonine kinase and its kinase activity is closely interrelated to cell cycle… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2011
2011
Application of a liquid chromatography-tandem mass spectrometry (LC/MS/MS) method to the pharmacokinetics of ON01910 in brain tumor-bearing mice.
ON01910 is a small molecular weight benzyl styryl sulfone currently under investigation as a novel anticancer agent. The purpose… (More)
  • figure 1
  • figure 2
  • table 1
Is this relevant?
2010
2010
Genetic approach to evaluate specificity of small molecule drug candidates inhibiting PLK1 using zebrafish.
During the preclinical drug discovery process it remains a challenge to enable early elimination of candidate molecules that may… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 5
  • figure 4
Is this relevant?
Review
2010
Review
2010
New emerging drugs targeting the genomic integrity and replication machinery in ovarian cancer
Ovarian cancer is a difficult to treat cancer entity with a high relapse rate. After initial surgery and chemotherapy, only a few… (More)
  • figure 1
  • figure 2
Is this relevant?
Highly Cited
2005
Highly Cited
2005
ON01910, a non-ATP-competitive small molecule inhibitor of Plk1, is a potent anticancer agent.
Elevated expression of polo-like kinase1 (Plk1) has been reported in many human tumors, and inhibition of Plk1 activity results… (More)
Is this relevant?